Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22076311 | 1.00 | MKNK2 (0.38) | MKNK2SCN9ASYKAAK1ALOX5AP | |
| SCHEMBL30411121 | 0.87 | MKNK2 (0.42) | MKNK2SYKAAK1SERPINE1PCSK9 | |
| SCHEMBL22105604 | 0.86 | MKNK2 (0.41) | MKNK2AAK1SERPINE1PCSK9 | |
| SCHEMBL25117838 | 0.85 | MKNK2 (0.42) | MKNK2AAK1ALOX5APFEN1SERPINE1 | |
| SCHEMBL22105605 | 0.85 | MKNK2 (0.41) | MKNK2SCN9AAAK1SERPINE1PCSK9 | |
| SCHEMBL30184391 | 0.85 | MKNK2 (0.42) | MKNK2AAK1ALOX5APFEN1SERPINE1 | |
| SCHEMBL28928900 | 0.85 | MKNK2 (0.42) | MKNK2AAK1ALOX5APFEN1SERPINE1 | |
| SCHEMBL25117835 | 0.82 | MKNK2 (0.39) | MKNK2SYKAAK1SERPINE1PCSK9 | |
| SCHEMBL29135641 | 0.82 | MKNK2 (0.44) | MKNK2SYKAAK1NQO2 | |
| SCHEMBL29135644 | 0.82 | MKNK2 (0.44) | MKNK2SYKAAK1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151641-A1 | MACROCYCLIC COMPOUNDS FOR TREATING CANCER | Turning Point Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220306652-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | Turning Point Therapeutics, Inc. | 2022-09-29 | — | — | US | disclosed |
| EP-3728271-B1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASES | TURNING POINT THERAPEUTICS INC (US) | 2022-09-28 | — | — | EP | disclosed |
| US-11286265-B2 | Macrocyclic compounds for treating disease | Turning Point Therapeutics, Inc. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | TP THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10745416-B2 | Macrocyclic compounds for treating disease | Turning Point Therapeutics, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286265-B2 | Macrocyclic compounds for treating disease | VHL, DLD, PC | MKNK2 2089/4885SCN9A 4671/4885SYK 2263/4885 |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | MKNK2 2089/4885SCN9A 4671/4885SYK 2263/4885 |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | MKNK2 2089/4885SCN9A 4671/4885SYK 2263/4885 |
| US-10745416-B2 | Macrocyclic compounds for treating disease | VHL, DLD, PC | MKNK2 2089/4885SCN9A 4671/4885SYK 2263/4885 |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | MAP3K20, LCK, MAP3K1 | MKNK2 104/4885SCN9A 1580/4885SYK 489/4885 |
| US-20220306652-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | MKNK2 2089/4885SCN9A 4671/4885SYK 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.